On December 3, 2024, the company announced groundbreaking results for its lead drug candidate, JANX007, a tumor-activated T-cell engager targeting advanced-stage prostate cancer.

U.S. stocks were mixed on Tuesday as investors digested new job openings data and awaited future remarks from Federal Reserve officials.

MicroStrategy has been making headlines once again, fueled by its audacious Bitcoin-centric strategy and a meteoric stock price rise of over 515% this year.